Security	Date	Code	Shares	A/D	Owned after	D/I	Nature of ownership
Common stock, $0.0001 par value^F1,F2	holding	—	—	—	2,655,977	D
Common stock, $0.0001 par value^F1,F3	holding	—	—	—	2,003,966	D
Common stock, $0.0001 par value^F1,F4	holding	—	—	—	347,970	D
Common stock, $0.0001 par value^F1,F5	holding	—	—	—	99,556	I	See footnote

Table II — derivative securities

Security	Conv. / exercise price	Date	Code	Shares	A/D	Exercisable	Expires	Underlying	Underlying shares	Owned after	D/I
Stock Option (Right to buy)^F1,F7,F9	$9.51	Jun 18, 2026	A	29,500	A	—	Jun 18, 2036	Common stock, $0.0001 par value	29,500	29,500	I
Pre-Funded Warrant^F1,F2,F6	$0.0001	holding	—	—	—	—	—	Common stock, $0.0001 par value	3,291,004	3,291,004	D
Pre-Funded Warrant^F1,F3,F6	$0.0001	holding	—	—	—	—	—	Common stock, $0.0001 par value	2,627,590	2,627,590	D
Pre-Funded Warrant^F1,F4,F6	$0.0001	holding	—	—	—	—	—	Common stock, $0.0001 par value	336,288	336,288	D
Stock Option (Right to buy)^F1,F7,F8	$4.08	holding	—	—	—	—	Jun 11, 2035	Common stock, $0.0001 par value	24,150	24,150	I
Stock Option (Right to buy)^F1,F7,F8	$12.36	holding	—	—	—	—	Jun 14, 2034	Common stock, $0.0001 par value	23,000	23,000	I
Stock Option (Right to buy)^F1,F7,F8	$7.84	holding	—	—	—	—	Jun 15, 2033	Common stock, $0.0001 par value	21,520	21,520	I
Stock Option (Right to buy)^F1,F7,F8	$3.61	holding	—	—	—	—	Jun 16, 2032	Common stock, $0.0001 par value	21,520	21,520	I
Stock Option (Right to buy)^F1,F7,F8	$27.66	holding	—	—	—	—	Jun 8, 2031	Common stock, $0.0001 par value	21,520	21,520	I
Stock Option (Right to buy)^F1,F7,F8	$19.00	holding	—	—	—	—	Nov 17, 2030	Common stock, $0.0001 par value	21,520	21,520	I
Stock Option (Right to buy)^F1,F7,F8	$19.00	holding	—	—	—	—	Nov 17, 2030	Common stock, $0.0001 par value	21,520	21,520	I
Stock Option (Right to buy)^F1,F7,F8	$19.00	holding	—	—	—	—	Nov 17, 2030	Common stock, $0.0001 par value	21,520	21,520	I

Explanation of responses

F1This Form 4 is filed jointly by Biotechnology Value Fund, L.P. ("BVF"), Biotechnology Value Fund II, L.P. ("BVF2"), Biotechnology Value Trading Fund OS LP ("Trading Fund OS"), BVF Partners OS Ltd. ("Partners OS"), BVF I GP LLC ("BVF GP"), BVF II GP LLC ("BVF2 GP"), BVF GP Holdings LLC ("BVF GPH"), BVF Partners L.P. ("Partners"), BVF Inc. and Mark N. Lampert (collectively, the "Reporting Persons"). Each of the Reporting Persons is a member of a Section 13(d) group with respect to the Issuer's outstanding shares of Common Stock. Each of the Reporting Persons disclaims beneficial ownership of the securities reported herein except to the extent of his or its pecuniary interest therein.
F2Securities owned directly by BVF. As the general partner of BVF, BVF GP may be deemed to beneficially own the securities owned directly by BVF. As the sole member of BVF GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF. As the investment manager of BVF, Partners may be deemed to beneficially own the securities owned directly by BVF. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF.
F3Securities owned directly by BVF2. As the general partner of BVF2, BVF2 GP may be deemed to beneficially own the securities owned directly by BVF2. As the sole member of BVF2 GP, BVF GPH may be deemed to beneficially own the securities owned directly by BVF2. As the investment manager of BVF2, Partners may be deemed to beneficially own the securities owned directly by BVF2. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by BVF2. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by BVF2.
F4Securities owned directly by Trading Fund OS. As the general partner of Trading Fund OS, Partners OS may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment manager of Trading Fund OS and the sole member of Partners OS, Partners may be deemed to beneficially own the securities owned directly by Trading Fund OS. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities owned directly by Trading Fund OS. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities owned directly by Trading Fund OS.
F5Securities held in a certain Partners managed account (the "Partners Managed Account"). Partners, as the investment manager of the Partners Managed Account, may be deemed to beneficially own the securities held by the Partners Managed Account. As the investment adviser and general partner of Partners, BVF Inc. may be deemed to beneficially own the securities held by the Partners Managed Account. As a director and officer of BVF Inc., Mr. Lampert may be deemed to beneficially own the securities held by the Partners Managed Account.
F6Each Pre-Funded Warrant may be exercised for one share of Common Stock. The Pre-Funded Warrants are exercisable immediately after the issue date and may be exercised at any time until all of the Pre-Funded Warrants are exercised in full. A holder of Pre-Funded Warrants (together with its affiliates and other attribution parties) may not exercise any portion of a Pre-Funded Warrant to the extent that immediately prior to or after giving effect to such exercise the holder would own more than 9.99% of the shares of Common Stock outstanding immediately after exercise.
F7Partners, BVF Inc. and Mr. Lampert may be deemed to have a pecuniary interest in the securities reported owned herein due to a certain agreement between Partners and Gorjan Hrustanovic, who serves on the Issuer's board of directors and as a member of Partners, pursuant to which Dr. Hrustanovic is obligated to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners. As such, Dr. Hrustanovic disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein.
F8The shares subject to the option have fully vested.
F9The shares subject to the option vest in a series of 12 successive equal monthly installments measured from June 18, 2026, subject to Dr. Hrustanovic's continuous service through each applicable vesting date. Such shares vest in full on the date of the Issuer's next annual meeting of stockholders if such stock option is not otherwise fully vested by such date, subject to Dr. Hrustanovic's continuous service through such vesting date.

Remarks

For purposes of Section 16 of the Securities Exchange Act of 1934, as amended, each of the Reporting Persons may be deemed to be a director by deputization of the Issuer due to a member of Partners, Gorjan Hrustanovic, serving on the Board of Directors of the Issuer, and his agreement to transfer the economic benefit, if any, received upon the sale of the shares issuable upon exercise of the securities reported owned herein to Partners.